The HZDR Technology Transfer Award 2025 has been awarded to the Hi-Acts Technology Lab team consisting of Dr. Martin Kreller, Dr. Santiago Brühlmann, and Dr. Martin Walther from the Institute of Radiopharmaceutical Cancer Research. The team successfully established the production of the radionuclides copper-61, copper-64, and copper-67 at HZDR, making a significant contribution to the development of novel copper-based radiopharmaceuticals in Europe. These compounds are considered particularly promising for modern cancer diagnostics and therapy. Through the radiopharmacy network “nukliD,” the team also supplies regional partner companies with copper radionuclides for the production of innovative cancer drugs.
Over the past three years, the work carried out in the Hi-Acts TechLab has enabled a substantial increase in the cyclotron-based production of copper radionuclides and their chemical processing into deliverable products. This achievement is reflected not only in the growing production capacity but also in the establishment of a strong customer network. Through its involvement in key European initiatives such as PRISMAP and Hi-Acts, HZDR has established itself as a leading European provider of copper radionuclides.
The increasing number of orders for copper radionuclides has also supported research activities across Europe, accelerating the development of innovative radiopharmaceuticals, particularly theranostic agents that combine diagnostic and therapeutic capabilities. The HZDR Technology Transfer Award is a well-deserved recognition of the TechLab team’s outstanding achievements. We warmly congratulate the award recipients on this success.
